Free tool
FAERS Monitor: Inrebic
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212327 or its brand name (Inrebic, Fedratinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,349
Serious
687
51% of reports
Hospitalization
266
Death reported
191
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea146
- death141
- nausea122
- fatigue115
- vomiting73
- constipation59
- off label use58
- haemoglobin decreased54
- asthenia52
- platelet count decreased50
- full blood count decreased45
- pruritus42
- anaemia41
- dizziness40
- drug ineffective40
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 46 |
| 2020 | 273 |
| 2021 | 282 |
| 2022 | 246 |
| 2023 | 184 |
| 2024 | 145 |
| 2025 | 106 |
| 2026 | 63 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,810 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| full blood count decreasedSignal | 45 | 34.9 | 26.2 | 1,446 |
| haemoglobin decreasedSignal | 54 | 8.2 | 6.3 | 336 |
| diarrhoeaSignal | 146 | 3.5 | 3.0 | 270 |
| anaemiaSignal | 41 | 3.4 | 2.5 | 66 |
| deathSignal | 141 | 2.6 | 2.2 | 137 |
| vomitingSignal | 73 | 2.4 | 1.9 | 61 |
| nauseaSignal | 122 | 2.4 | 2.0 | 102 |
| fatigueSignal | 115 | 2.3 | 1.9 | 87 |
| astheniaSignal | 52 | 2.2 | 1.7 | 32 |
| pruritus | 42 | 1.7 | 1.3 | 12 |
| dizziness | 40 | 1.3 | 0.9 | 2 |
| off label use | 58 | 1.0 | 0.8 | 0 |
| drug ineffective | 40 | 0.5 | 0.3 | 24 |
| constipation | 59 | 0.0 | 0.0 | 905,229 |
| platelet count decreased | 50 | 0.0 | 0.0 | 764,784 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.